Associated Genetic Biomarkers
MGMT is altered in 0.05% of all cancers with conventional glioblastoma multiforme, melanoma, adenocarcinoma of unknown primary, astrocytoma, and bladder urothelial carcinoma having the greatest prevalence of alterations .
The most common alterations in MGMT are MGMT Mutation (0.46%), MGMT *239S (0.07%), MGMT A82V (0.07%), MGMT E197K (0.07%), and MGMT G162* (0.07%) .
MGMT status serves as an inclusion eligibility criteria in 3 clinical trials, of which 3 are open and 0 are closed. Of the trials that contain MGMT status as an inclusion criterion, 3 are phase 2 (3 open).
Trials with MGMT status in the inclusion eligibility criteria most commonly target glioblastoma, gliosarcoma, anaplastic astrocytoma, colorectal adenocarcinoma, and colorectal carcinoma .
The most frequent alterations to serve as inclusion eligibility criteria are MGMT Promoter Methylation Negative, MGMT Promoter Methylation Positive, MGMT Deficient Expression, MGMT Expression, and MGMT Loss .
Radiation therapy, temozolomide, nivolumab, ipilimumab, and pembrolizumab are the most frequent therapies in trials with MGMT as an inclusion criteria .
Significance of MGMT in Diseases
Breast Carcinoma +
Colorectal Adenocarcinoma +
MGMT is an inclusion criterion in 1 clinical trial for colorectal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains MGMT status and colorectal adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) .
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.